GenSci was founded in 1997 and is widely recognized as the first biopharmaceutical company established in China. GenSci currently has around 7,000 full time employees worldwide and is renowned for the contributions it has made to improving children’s health and women’s health. In 2014, GenSci launched the world’s first long-acting growth hormone product through the PEG technology, and in 2022, its revenue surpassed RMB 10 billion, a significant commercial landmark for GenSci. GenSci’s growth hormone products currently account for over 75% of growth hormone products available on the market in China. Its therapeutic scope has been further expanded to adult endocrinology, immunology, oncology and pulmonary diseases. While GenSci has strong footprints in China, it is looking for strategic partners to develop and commercialize GenSci’s innovative pipeline outside of China, especially in the U.S. and European markets.